ValuEngine cut shares of Minerva Neurosciences, Inc (NASDAQ:NERV) from a sell rating to a strong sell rating in a research report report published on Monday, May 29th.

Other equities analysts have also recently issued reports about the company. Jefferies Group LLC started coverage on Minerva Neurosciences in a report on Monday, March 6th. They set a buy rating and a $17.00 price target on the stock. Zacks Investment Research raised Minerva Neurosciences from a sell rating to a hold rating in a report on Tuesday, May 16th.

Shares of Minerva Neurosciences (NASDAQ:NERV) opened at 9.65 on Monday. The company’s market cap is $354.19 million. Minerva Neurosciences has a 1-year low of $6.50 and a 1-year high of $14.92. The firm has a 50-day moving average price of $8.13 and a 200 day moving average price of $9.57.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). On average, equities analysts anticipate that Minerva Neurosciences will post ($1.50) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/16/minerva-neurosciences-inc-nerv-cut-to-strong-sell-at-valuengine-updated-updated.html.

In other news, Director Marc D. Beer acquired 50,000 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was acquired at an average price of $8.12 per share, with a total value of $406,000.00. Following the completion of the purchase, the director now directly owns 25,000 shares in the company, valued at $203,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 21.60% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC raised its position in shares of Minerva Neurosciences by 7.4% in the first quarter. Teachers Advisors LLC now owns 31,226 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 2,141 shares during the last quarter. ClariVest Asset Management LLC raised its position in shares of Minerva Neurosciences by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 300 shares during the last quarter. TD Asset Management Inc. raised its position in shares of Minerva Neurosciences by 1.3% in the first quarter. TD Asset Management Inc. now owns 27,100 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 357 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Minerva Neurosciences by 35.7% in the first quarter. Handelsbanken Fonder AB now owns 95,000 shares of the biopharmaceutical company’s stock worth $770,000 after buying an additional 25,000 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Minerva Neurosciences by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 1,286 shares during the period. 70.33% of the stock is owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.